RESUMO
Combination therapies have been studied by many researchers using different techniques and methods to solve some solid drug problems and improve more effective treatments for humans and animals. One of the more significant findings to emerge from this study is that the combination of pharmaceutical agents by using pharmaceutical deep eutectic solvents (PDESs) in order to produce dual action drugs and reduce the drug resistance. The major objective of this study was to investigate the dual functionality of drugs (antioxidant and antibacterial activity) via the principle of PDESs. The produced PDESs were characterized via different techniques, namely differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR), and UV-Vis spectrophotometry. We herein tested a panel of novel liquid formulations of didecyldimethylammonium bromide (DDMAB) against a selection of pathogenic bacteria, classifying their spectrum of activity against Gram-positive and Gram-negative bacteria. The current study found that the PDESs can be used to produce drugs with dual functionalities. The produced PDES from (ascorbic acid: DDMAB) exhibits stronger antibacterial activity against Gram-positive Staphyloccocus aureus and Staphyloccocus epidermidis than gram negatives. One of the most interesting PDESs studied in this research was that of DDMAB and ascorbic acid. This forms a eutectic which is far from the solid drugs issues and shows dual functionality like antibacterial and antioxidant activity. This study has found that there is a correlation between the molecular docking study and the biological activities of the combined drugs.
Assuntos
Antioxidantes , Solventes Eutéticos Profundos , Compostos de Amônio Quaternário , Animais , Humanos , Antioxidantes/farmacologia , Antibacterianos/farmacologia , Composição de Medicamentos , Simulação de Acoplamento Molecular , Bactérias Gram-Negativas , Bactérias Gram-Positivas , Ácido Ascórbico , Preparações FarmacêuticasRESUMO
Racemization has a large impact upon the biological properties of molecules but the chemical scope of compounds with known rate constants for racemization in aqueous conditions was hitherto limited. To address this remarkable blind spot, we have measured the kinetics for racemization of 28 compounds using circular dichroism and 1 Hâ NMR spectroscopy. We show that rate constants for racemization (measured by ourselves and others) correlate well with deprotonation energies from quantum mechanical (QM) and group contribution calculations. Such calculations thus provide predictions of the second-order rate constants for general-base-catalyzed racemization that are usefully accurate. When applied to recent publications describing the stereoselective synthesis of compounds of purported biological value, the calculations reveal that racemization would be sufficiently fast to render these expensive syntheses pointless.
RESUMO
In recent times, the methods used to evaluate gastric ulcer healing worldwide have been based on visual examinations and estimating ulcer dimensions in experimental animals. In this study, the protective effect of rhodanine and 2,4-thiazolidinediones scaffolds compared to esomeprazole was investigated in an ethanol model of stomach ulcers in rats. Pretreatment with experimental treatments or esomeprazole prevented the development of ethanol-induced gastric ulcers. The severity of the lesions and injuries was significantly lower than that of vehicle (10% Tween 80) treated rats. Significant and excellent results were obtained with the compound 6 group, with inhibition percentage and ulcer area values of 97.8% and 12.8 ± 1.1 mm2, respectively. Synthesized compounds 2, 7 and 8 exhibited inhibition percentages and ulcer areas of 94.3% and 31.2 ± 1.1 mm2, 91. 3% and 48.1 ± 0. 8 mm2, 89. 5% and 57. 6 ± 1. 2 mm2, and 89. 1% and 60.3 ± 0. 8 mm2, respectively. These biological outcomes are consistent with the docking studies in which Compounds 7 and 8 showed remarkable binding site affinities toward human H+/K+-ATPase α protein (ID: P20648), rat H+/K+-ATPase α protein (ID: P09626), and Na+/K+-ATPase crystal structure (PDB ID:2ZXE) with binding site energies of - 10.7, - 9.0, and - 10.4 (kcal/mol) and - 8.7, - 8.5, and - 8.0 (kcal/mol), respectively. These results indicate that these test samples were as effective as esomeprazole. Likewise, immunohistochemical staining of antiapoptotic (BCL2) and tumor suppressor (P53) proteins showed strong positive marks in the10% Tween 80- treated group, opposing the mild staining results for the esomeprazole-treated group. Similarly, the staining intensity of the group treated with Compounds 2-8 was variable for both proteins.
Assuntos
Antiulcerosos , Rodanina , Úlcera Gástrica , Tiazolidinedionas , Humanos , Ratos , Animais , Esomeprazol/uso terapêutico , Rodanina/metabolismo , Rodanina/farmacologia , Rodanina/uso terapêutico , Proteína Supressora de Tumor p53/metabolismo , Mucosa Gástrica/metabolismo , Antiulcerosos/uso terapêutico , Úlcera/patologia , Polissorbatos/farmacologia , Tiazolidinedionas/uso terapêutico , Úlcera Gástrica/induzido quimicamente , Úlcera Gástrica/tratamento farmacológico , Úlcera Gástrica/patologia , Extratos Vegetais/farmacologia , Etanol/farmacologia , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Adenosina Trifosfatases/metabolismoRESUMO
In the present study, the hepatoprotective effect of 5-benzylidine-2-thiohydantoin (5B2T), a unique derivative of the thiohydantoin group, on liver injury induced by diethylnitrosamine (DEN) in male rats was investigated. The experimental animals were divided into three groups, each with 14 rats. Rats in group I were considered to be controls and received only 10% Tween 80. Rats in group II were injected with 200 mg/kg DEN intraperitoneally. Rats in group III were injected with a single dose of DEN 200 mg/kg intraperitoneally and received the treatment orally (50 mg/kg, 5B2T) for two durations, 3 and 6 weeks. At the end of the experiment, blood was collected for the analysis of liver function and pro-inflammatory cytokine IL-6 and tumor necrosis factor α (TNF-α) levels. Additionally, liver specimens were used for histopathological examination and immunohistochemistry. The single intraperitoneal injection of 200 mg/kg DEN into rats resulted in significant elevation of serum enzyme levels of AST, ALT and ALP, which are indicators of hepatocellular damage, along with elevation in TNF-α and IL-6 in the DEN group. The results of both LFTs and ELISA in the treatment group showed improvements and a decline in the levels of the markers. Histopathological examination showed fibrosis, necrosis and infiltration of inflammatory cells in the DEN group, with lower intensity in the treatment group. The results of immunohistochemical staining revealed strong positive staining of both HSA and Ki-67 antibodies in the DEN group, with much lower intensity in the treatment group. The results of the docking study indicated that 5B2T has a remarkable interaction with TNF-α (PDB ID: 1TNF) and human IL-6 (PDB ID: 1IL6) with binding site energies of - 7.1 and - 6.1 (kcal/mol), respectively. The correct absorption and binding between the drug and the receptor was evaluated through computerized molecular docking by using the AutoDock program. The conclusion of the results from the current study reflected the interesting hepatoprotective abilities of 5B2T against DEN-induced hepatocellular damage and cancer in experimental rats.
Assuntos
Doença Hepática Crônica Induzida por Substâncias e Drogas , Neoplasias Hepáticas Experimentais , Humanos , Ratos , Masculino , Animais , Dietilnitrosamina/toxicidade , Fator de Necrose Tumoral alfa/metabolismo , Interleucina-6/metabolismo , Simulação de Acoplamento Molecular , Fígado/metabolismo , Neoplasias Hepáticas Experimentais/patologiaRESUMO
INTRODUCTION: Racemization has long been an ignored risk in drug development, probably because of a lack of convenient access to good tools for its detection and an absence of methods to predict racemization risk. As a result, the potential effects of racemization have been systematically underestimated. Areas covered: Herein, the potential effects of racemization are discussed through a review of drugs for which activity and side effects for both enantiomers are known. Subsequently, drugs known to racemize are discussed and the authors review methods to predict racemization risk. Application of a method quantitatively predicting racemization risk to databases of compounds from the medicinal chemistry literature shows that success in clinical trials is negatively correlated with racemization risk. Expert opinion: It is envisioned that a quantitative method of predicting racemization risk will remove a blind spot from the drug development pipeline. Removal of the blind spot will make drug development more efficient and result in less late-stage attrition of the drug pipeline.